CARMEL, Ind., April  03, 2026  (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide

MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MBX Biosciences Grants Equity Award to New Chief Business Officer

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>CARMEL, Ind., April  03, 2026  (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>MBX Biosciences has issued a stock option award to Karen Basbaum, its new Chief Business Officer, totaling 130,000 shares at an exercise price of $32.29. This strategic hire could lead to enhanced partnerships and developments within MBX&#039;s promising pipeline of endocrinology and metabolic therapies.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>MBX issued stock options worth 130,000 shares to new CBO.</li><li>Options have an exercise price of $32.29 per share.</li><li>Award vests over four years, starting on March 9, 2027.</li><li>MBX&#039;s pipeline includes candidates for chronic hypoparathyroidism and obesity.</li><li>New CBO likely to enhance strategic direction and partnerships.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>MBX Biosciences (MBX)</strong>: MBX&#039;s strategic hiring may enhance its pipeline and market presence.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This news falls under Corporate Developments as it involves key personnel changes that may drive strategic direction and operational effectiveness.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>The appointment of a new CBO could signal upcoming growth strategies.</li><li>130,000 stock options may incentivize stronger company performance.</li><li>Pipeline advancements could attract investors, influencing share price positively.</li><li>Potential partnerships may materialize under new leadership, boosting market position.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Karen Basbaum&#039;s stock options total 130,000 shares.</li><li>Exercise price for options is set at $32.29.</li><li>Options will vest over four years from March 9, 2026.</li><li>MBX is progressing candidate MBX 2109 into Phase 3 development.</li><li>Company’s focus remains on precision peptide therapies for endocrine disorders.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider accumulating MBX shares as new leadership can drive growth catalysts over 12-24 months.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>CARMEL, Ind., April  03, 2026  (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/MBX">MBX</a>), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the issuance of an equity inducement award to Karen Basbaum in connection with her commencement of employment as the company's new Chief Business Officer.</p>  <p>The inducement award consisted of non-qualified stock options to purchase an aggregate of 130,000 shares of the company's common stock with an exercise price of $32.29 per share, which is equal to the closing price of the company's common stock as reported by Nasdaq on April 1, 2026. The option has a 10-year term and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of March 9, 2026, and the remainder vesting in 36 equal monthly installments for the three years thereafter, subject to Ms. Basbaum's continued service. The award is subject to the terms and conditions of the company's 2026 Inducement Plan and the terms and conditions of the stock option agreement covering the grant.</p>  <p>The award was approved by the company's board of directors as an inducement material to Ms. Basbaum entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). To comply with the terms of this exemption, the employment inducement awards require an immediate public announcement of the award and written notice to the Nasdaq Stock Market.</p>  <p><strong>About MBX Biosciences </strong></p>  <p>MBX Biosciences is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP&#x2122; platform, for the treatment of endocrine and metabolic disorders. The company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The company's pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism (HP) preparing for Phase 3 development; an obesity portfolio that includes MBX 4291 in Phase 1 development, as well as multiple discovery and pre-clinical obesity candidates; and imapextide (MBX 1416) for the treatment of post-bariatric hypoglycemia (PBH) in Phase 2 development. The company is based in Carmel, Indiana. To learn more, please visit the company website at <a href="http://www.mbxbio.com" title="www.mbxbio.com">www.mbxbio.com</a> and follow it on LinkedIn.</p>  <p><strong>Media Contact:</strong></p>  <p>George Shea<br></br>We. Communications<br></br>gshea@wecommunications.com<br></br>(937) 232-4889</p>  <p><strong>Investor Contact:</strong></p>  <p>Jim DeNike<br></br>MBX Biosciences<br></br>jdenike@mbxbio.com</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY4MzYzNiM3NTE4MTk1IzIyNDUzNzQ="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/ZjMyZDdiOWQtMzMyOS00ZWI5LWJkMTQtYTZhNmE0YTViMTlkLTEyNTY5MjctMjAyNi0wNC0wMy1lbg==/tiny/MBX-Biosciences-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/5499b327-bce0-4a3f-96a7-04a38b68a99f"><img src="https://ml.globenewswire.com/media/5499b327-bce0-4a3f-96a7-04a38b68a99f/small/mbx-logos-final-full-jpg.jpg" border="0" width="150" height="59" alt="Primary Logo"></img></a></p>

MBX Biosciences has issued a stock option award to Karen Basbaum, its new Chief Business Officer, totaling 130,000 shares at an exercise price of $32.29. This strategic hire could lead to enhanced partnerships and developments within MBX's promising pipeline of endocrinology and metabolic therapies.

MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News